Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

KZR

Kezar Life Sciences Inc

Sep 12 • 04:00PM ET

3.95

-0.03 -0.75 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN GILD INCY NBIX CYTK RCUS ZYME FATE CAAP KALA

| Held by: VTI VXF IWC DFAT DFAS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-9.69	Insider Own	14.84%	Shs Outstand	7.32M	Perf Week	-2.95%
Market Cap	28.91M	Forward P/E	-	EPS next Y	-6.02	Insider Trans	-0.08%	Shs Float	6.24M	Perf Month	0.77%
Enterprise Value	-59.87M	PEG	-	EPS next Q	-2.08	Inst Own	60.18%	Short Float	12.82%	Perf Quarter	-17.54%
Income	-70.79M	P/S	-	EPS this Y	28.75%	Inst Trans	10.78%	Short Ratio	15.52	Perf Half Y	-32.25%
Sales	0.00M	P/B	0.31	EPS next Y	26.47%	ROA	-48.98%	Short Interest	0.80M	Perf YTD	-41.22%
Book/sh	12.55	P/C	0.29	EPS next 5Y	19.61%	ROE	-58.39%	52W High	9.18 -56.97%	Perf Year	-29.46%
Cash/sh	13.78	P/FCF	-	EPS past 3/5Y	-3.52% 8.98%	ROIC	-74.71%	52W Low	3.62 9.11%	Perf 3Y	-95.92%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	2.53% 3.52%	Perf 5Y	-91.49%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	28.44%	Oper. Margin	-	ATR (14)	0.15	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.29	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	46.16	Recom	1.80
Dividend Gr. 3/5Y	- -	Current Ratio	7.29	EPS Q/Q	36.63%	SMA20	-0.04%	Beta	0.62	Target Price	12.50
Payout	-	Debt/Eq	0.13	Sales Q/Q	-	SMA50	-5.14%	Rel Volume	0.07	Prev Close	3.98
Employees	55	LT Debt/Eq	0.03	Earnings	Aug 13 AMC	SMA200	-23.02%	Avg Volume	51.54K	Price	3.95
IPO	Jun 21, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	16.38% -	Trades		Volume	3,749	Change	-0.75%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-11-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$4
Mar-16-23	Downgrade	William Blair	Outperform → Mkt Perform
Dec-08-21	Initiated	Wells Fargo	Overweight	$19
Jul-16-18	Initiated	William Blair	Outperform
Jul-16-18	Initiated	Wells Fargo	Outperform	$30
Jul-16-18	Initiated	Jefferies	Buy

Aug-28-25 04:01PM	Kezar Life Sciences to Participate in Two Upcoming Investor Conferences (Business Wire)
Aug-13-25 04:01PM	Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Jul-15-25 04:41PM	Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (Business Wire)
May-28-25 04:01PM	Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference (Business Wire) +5.48%
May-27-25 12:00PM	Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
04:01PM	Loading…
May-13-25 04:01PM	Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Mar-25-25 06:54PM	Kezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript) (SeekingAlpha) -8.44% -8.33%
07:30AM	Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results (Business Wire)
Mar-24-25 08:00AM	Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025 (Business Wire)
Feb-18-25 04:01PM	Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025 (Business Wire) +6.78%
Nov-13-24 12:30PM	Kezar struck again with second FDA hold (Clinical Trials Arena)
Nov-12-24 04:01PM	Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Oct-28-24 08:30AM	Kezar Life Sciences Announces 1-for-10 Reverse Stock Split (Business Wire)
Oct-18-24 11:02AM	Kezar Life Sciences discontinues lupus nephritis programme after fatalities (Clinical Trials Arena)
Oct-17-24 01:37PM	Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study (Benzinga) -8.80%
08:35AM	Loading…
08:35AM	Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan (Business Wire)
08:30AM	Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update (Business Wire)
Oct-15-24 12:00PM	What Makes Kezar Life Sciences (KZR) a New Buy Stock (Zacks)
Oct-10-24 08:30AM	Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal (Business Wire)
Oct-08-24 07:04PM	TANG CAPITAL MANAGEMENT LLC Acquires New Stake in Kezar Life Sciences Inc (GuruFocus.com) +16.80%
Oct-07-24 08:50AM	FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths (Benzinga)
04:52AM	FDA places hold on Kezar Life Sciences trial for lupus nephritis treatment (Clinical Trials Arena)
Oct-04-24 05:00PM	Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis (Business Wire)
Oct-01-24 04:52AM	Kezar Life Sciences suspends subject enrolment in trial of lupus nephritis drug (Clinical Trials Arena)
Sep-30-24 08:30AM	Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients (Business Wire) +42.16%
Sep-04-24 04:01PM	Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-14-24 11:13AM	Kezar stalls solid tumour trial to focus on autoimmune disease candidate (Pharmaceutical Technology) +5.05%
Aug-13-24 04:02PM	Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-10-24 04:01PM	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) +10.28%
Jun-07-24 05:59PM	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) +5.07%
04:01PM	Loading…
May-29-24 04:01PM	Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-09-24 10:57PM	KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q1 2024 (InvestorPlace) -5.42%
04:01PM	Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-06-24 04:05PM	Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Apr-08-24 05:38PM	13 Best Penny Stocks to Buy According to Billionaire Ken Griffin (Insider Monkey)
04:01PM	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Mar-27-24 04:30PM	From Pennies to Fortunes: 3 Stocks Set to Make Millionaires (InvestorPlace)
Mar-16-24 06:56AM	Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026 (InvestorPlace)
Mar-14-24 09:54PM	KZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023 (InvestorPlace) -6.59%
04:01PM	Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update (Business Wire)
Mar-08-24 04:05PM	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Feb-28-24 04:01PM	Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference (Business Wire) +7.27%
Feb-26-24 06:30PM	Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis (Business Wire) +8.18%
Feb-25-24 02:12PM	3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond (InvestorPlace)
Feb-02-24 05:37AM	3 Penny Stocks Poised for an Unbelievable 1,000% Jump (InvestorPlace)
Dec-18-23 08:51AM	Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth (InvestorPlace)
Nov-21-23 04:01PM	Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-13-23 04:01PM	Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire) +7.60%
Nov-03-23 04:03PM	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) +6.25%
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE)
Oct-23-23 10:08AM	12 Best Penny Stocks to Buy Under $1 (Insider Monkey)
Oct-09-23 05:56PM	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) +13.43%
Oct-04-23 09:32AM	Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce (Zacks)
Oct-03-23 04:10PM	Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer (Business Wire) -9.57%
Sep-20-23 06:30PM	Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia (Business Wire)
Aug-31-23 04:01PM	Kezar Life Sciences to Participate in Three Upcoming Investor Conferences (Business Wire) -8.59% +5.37%
Aug-10-23 04:01PM	Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update (Business Wire) -26.34%
Aug-04-23 04:03PM	Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jul-07-23 04:01PM	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jun-09-23 04:01PM	Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
May-31-23 07:00AM	Kezar Life Sciences to Participate in the Jefferies Healthcare Conference (Business Wire)
May-11-23 04:01PM	Kezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Apr-05-23 04:01PM	Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -13.87% +6.36%
Mar-14-23 04:01PM	Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update (Business Wire) -11.00%
Mar-13-23 07:00AM	Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023 (Business Wire) +10.99%
Mar-06-23 07:00AM	Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023 (Business Wire)
Mar-03-23 06:17PM	Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Mar-01-23 04:01PM	Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference (Business Wire) -10.73%
Feb-06-23 04:01PM	Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
11:44AM	A Kezar Life Sciences, Inc. (NASDAQ:KZR) insider increased their holdings by 9.9% last year (Simply Wall St.)
Jan-26-23 06:44AM	Daily Vickers Top Buyers & Sellers for 01/26/2023 (Argus Research)
Jan-13-23 04:01PM	Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jan-06-23 07:04AM	Daily Vickers Top Buyers & Sellers for 01/06/2023 (Argus Research)
Jan-04-23 04:01PM	Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-07-22 04:01PM	Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Nov-14-22 07:00AM	Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022 (Business Wire)
Nov-11-22 04:01PM	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) +5.39%
Nov-10-22 04:01PM	Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update (Business Wire) +13.15%
Nov-09-22 04:01PM	Kezar Life Sciences to Participate in Two Upcoming Investor Conferences (Business Wire) -8.71%
Nov-03-22 10:00AM	Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASNs Kidney Week 2022 Annual Meeting (Business Wire)
Oct-14-22 07:00AM	Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrologys Kidney Week 2022 Annual Meeting (Business Wire)
Oct-06-22 04:01PM	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -6.16%
Oct-03-22 04:01PM	Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis (Business Wire)
Sep-29-22 04:05PM	Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022 (Business Wire)
Sep-02-22 04:30PM	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Sep-01-22 07:00AM	Kezar Life Sciences to Participate in Three Upcoming Investor Conferences (Business Wire)
Aug-30-22 12:10PM	A Kezar Life Sciences, Inc. (NASDAQ:KZR) insider increased their holdings by 9.9% last year (Simply Wall St.)
Aug-11-22 04:01PM	Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update (Business Wire) +6.05%
Aug-03-22 04:30PM	Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jul-18-22 09:55AM	Wall Street Analysts See an 82% Upside in Kezar Life Sciences, Inc. (KZR): Can the Stock Really Move This High? (Zacks) -5.45%
Jul-11-22 04:30PM	Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position (Business Wire)
Jul-08-22 02:42PM	Kezar Life Sciences Stock Shows Rising Market Leadership: Earns 81 RS Rating (Investor's Business Daily)
Jul-07-22 04:30PM	Kezar Life Sciences to Present at the William Blair Biotech Focus Conference (Business Wire)
Jul-06-22 04:30PM	Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jun-30-22 01:08PM	Biotech ETF Tops in June: 5 Stocks That Outperform (Zacks)
09:55AM	Wall Street Analysts Think Kezar Life Sciences, Inc. (KZR) Could Surge 135%: Read This Before Placing a Bet (Zacks)
Jun-28-22 03:57PM	Wells Fargo Beefs Up Kezar Life Price Target - Read Why (Benzinga) +43.43%
11:58AM	Why Kezar Life Sciences Stock Is Crushing It Today (Motley Fool)
10:23AM	Kezar (KZR) Doubles on Promising Kidney Disorder Study Data (Zacks)
09:58AM	Healthcare Breakthroughs: KZR, NMLSF, AGRX, LMLLF Report Latest Advances in Novel Therapeutics for Inflammatory Diseases, Oncology, and Autism (GlobeNewswire)

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 19, 2015 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chiang Pichi Luo	SVP, Corporate Controller	Jul 02 '25	Sale	4.28	264	1,130	2,711	Jul 03 04:15 PM
Schiller Mark C.	Chief Operating Officer	Jul 02 '25	Sale	4.28	561	2,401	2,739	Jul 03 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KZR

Kezar Life Sciences Inc

Upgrade your FINVIZ experience